Progression-free survival end points in prostate cancer: are we truly making progress

被引：0
|
作者：
Madan, Ravi A. [1 ]
Posadas, Edwin M. [2 ]
Lee, Richard J. [3 ]
机构：
[1] NCI, Genitourinary Malignancies Branch, Bethesda, MD 20892 USA
[2] Samuel Oschin Comprehens Canc Inst, Cedars Sinai Med Ctr, Los Angeles, CA USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Dept Med, Boston, MA USA
来源：
NATURE REVIEWS UROLOGY | 2024年
关键词：
PHASE-III; PREDNISONE; DOCETAXEL;
D O I：
10.1038/s41585-024-00902-x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Recently, several therapeutic strategies in prostate cancer have been granted regulatory approval based on progression-free survival benefits alone, which is a relative change in the therapeutic development of prostate cancer treatments. Previously, overall survival was a requirement for approvals. Whether this approach is warranted or beneficial to patients remains unclear.
引用
收藏
页码：646 / 648
页数：3
相关论文
共 50 条
  • [21] Toward progression-free survival as a primary end point in advanced colorectal cancer
    Yothers, Greg
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5153 - 5154
  • [22] Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer
    Garside, Jamie
    Shen, Qin
    Westermayer, Bernd
    van de Ven, Michiel
    Kroep, Sonja
    Chirikov, Viktor
    Juhasz-Boess, Ingolf
    CLINICAL THERAPEUTICS, 2023, 45 (10) : 983 - 990
  • [23] Progression-Free Survival as a Predictor of Overall Survival in Men With Castrate-Resistant Prostate Cancer
    Halabi, Susan
    Vogelzang, Nicholas J.
    Ou, San-San
    Owzar, Kouros
    Archer, Laura
    Small, Eric J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (17) : 2766 - 2771
  • [24] Progression-free survival with regorafenib in gastric cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2016, 17 (08): : E323 - E323
  • [25] SIRFLOX: Progression-Free Survival in the Liver As a Surrogate End Point for Survival?
    Ayoola, Adeola O.
    Ibraheem, Abiola F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) : 4193 - +
  • [26] Is It Premature to Accept Radiographic Progression-Free Survival as a Surrogate End Point in Metastatic Hormone-Sensitive Prostate Cancer?
    Garcia, Jorge A.
    Spratt, Daniel E.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (24)
  • [27] Associations between Body Mass Index and Prostate Cancer: The Impact on Progression-Free Survival
    Popovici, Dorel
    Stanisav, Cristian
    Pricop, Marius
    Dragomir, Radu
    Saftescu, Sorin
    Ciurescu, Daniel
    MEDICINA-LITHUANIA, 2023, 59 (02):
  • [28] Progression-free survival is a surrogate for survival in advanced colorectal cancer
    Buyse, Marc
    Burzykowski, Tomasz
    Carroll, Kevin
    Michiels, Stefan
    Sargent, Daniel J.
    Miller, Langdon L.
    Elfring, Gary L.
    Pignon, Jean-Pierre
    Piedbois, Pascal
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5218 - 5224
  • [29] Making Progress on Progression in Metastatic Prostate Cancer
    Armstrong, Andrew J.
    Halabi, Susan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (12) : 1322 - U17
  • [30] Association of calcium channel blocker use with prostate cancer aggressiveness, progression-free survival, and overall survival
    Poch, Michael Adam
    Mehedint, Diana
    Curtis, Alexandra
    Attwood, Kristopher
    Wilding, Gregory E.
    Ondracek, Rochelle Payne
    Underwood, Willie
    Schwaab, Thomas
    Guru, Khurshid
    Mohler, James
    Heemers, Hannelore
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345